IMPACT BIOMEDICAL INC.
For the period ended Jun 30, 2025. Filed Aug 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 14, 2025
IBO$4.62+6.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 1. Condensed Consolidated Balance Sheets as of June 30, 2025 (Unaudited) and December 31, 2024
Condensed Consolidated Balance Sheets
| June 30, 2025 (unaudited) | December 31, 2024 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $624,000 | $1,999,000 |
| Inventory | 486,000 | - |
| Current portion of notes receivable | 200,000 | 184,000 |
| Prepaid expenses and other current assets | 171,000 | 265,000 |
| Total current assets | 1,481,000 | 2,448,000 |
| Property, plant and equipment, net | 14,000 | 17,000 |
| Notes receivable | - | 17,000 |
| Other intangible assets, net | 17,565,000 | 17,808,000 |
| Total assets | $19,060,000 | $20,290,000 |
| LIABILITIES AND STOCKHOLDERS’ DEFICIT EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $554,000 | $713,000 |
| Accrued expenses and deferred revenue | 266,000 | 194,000 |
| Note payable, related party | 22,352,000 | 8,878,000 |
| Total current liabilities | 23,172,000 | 9,785,000 |
| Deferred tax liability, net | 3,268,000 | 3,268,000 |
| Total liabilities | 26,440,000 | 13,053,000 |
| Commitments and contingencies (Note 12) | - | |
| Stockholders’ (deficit) equity | ||
| Preferred stock, $.001 par value; 100,000,000 shares authorized, 60,496,041 shares issued and outstanding (60,496,041 on December 31, 2024); Liquidation value $0.001 per share, 60,496,041 aggregate. (60,496,041 on December 31, 2024). | 60,000 | 60,000 |
| Common stock, $.001 par value; 4,000,000,000 shares authorized, 12,185,412 shares issued and outstanding (10,000,000 on December 31, 2024) | 12,000 | 11,000 |
| Additional paid-in capital | 42,870,000 | 41,857,000 |
| Accumulated deficit | (53,283,000) | (37,669,000) |
| Total stockholders’ (deficit) equity of the Company | (10,341,000) | 4,259,000 |
| Non-controlling interest in subsidiaries | 2,961,000 | 2,978,000 |
| Total stockholders’ (deficit) equity | (7,380,000) | 7,237,000 |
| Total liabilities and stockholders’ (deficit) equity | $19,060,000 | $20,290,000 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.